PAVmed (PAVM) 10-Q 6 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 04, 2020
Cover [Abstract]
Entity Registrant Name	PAVmed Inc.
Entity Central Index Key	0001624326
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		52,254,847
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 8,293	$ 6,219
Prepaid expenses, deposits, and other current assets	1,487	328
Total current assets	9,780	6,547
Other assets	724	693
Total assets	10,504	7,240
Current liabilities:
Accounts payable	3,207	2,353
Accrued expenses and other current liabilities	1,538	1,386
Current portion debt - Cares Act Paycheck Protection Program note payable	200
Senior Secured Convertible Notes - at fair value	15,620	8,139
Senior Convertible Note - at fair value	4,600
Total current liabilities	25,165	11,878
Cares Act Paycheck Protection Program note payable	100
Total liabilities	25,265	11,878
Commitments and contingencies (Note 5)
Stockholders' Equity (Deficit):
Common stock, $0.001 par value. Authorized, 150,000,000 shares; issued and outstanding, 49,655,915 shares at September 30, 2020 and 40,478,861 shares at December 31, 2019	50	41
Additional paid-in capital	64,050	47,554
Accumulated deficit	(79,461)	(53,715)
Total PAVmed Inc. Stockholders' Deficit	(12,898)	(3,824)
Noncontrolling interests	(1,863)	(814)
Total Stockholders' Equity (Deficit)	(14,761)	(4,638)
Total Liabilities and Stockholders' Equity (Deficit)	10,504	7,240
Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,203,488 at September 30, 2020 and 1,158,209 shares at December 31, 2019	$ 2,463	$ 2,296

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	49,655,915	40,478,861
Common stock, shares outstanding	49,655,915	40,478,861
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,203,488	1,158,209
Preferred stock, shares outstanding	1,203,488	1,158,209

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue
Operating expenses:
General and administrative	2,909	1,724	8,474	5,331
Research and development	2,619	1,520	7,321	4,376
Total operating expenses	5,528	3,244	15,795	9,707
Loss from operations	(5,528)	(3,244)	(15,795)	(9,707)
Other income (expense):
Interest expense			(53)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note	367	379	(5,521)	(341)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note	(50)		(660)
Debt extinguishments loss - Senior Secured Convertible Notes	(663)	(407)	(4,600)	(666)
Other income (expense), net	(346)	(28)	(10,834)	(1,007)
Loss before provision for income tax	(5,874)	(3,271)	(26,629)	(10,714)
Provision for income taxes
Net loss before noncontrolling interests	(5,874)	(3,271)	(26,629)	(10,714)
Net loss attributable to the noncontrolling interests	391	186	1,093	501
Net loss attributable to PAVmed Inc.	(5,483)	(3,085)	(25,536)	(10,213)
Less: Series B Convertible Preferred Stock dividends earned	(74)	(68)	(215)	(201)
Net loss attributable to PAVmed Inc. common stockholders	$ (5,557)	$ (3,153)	$ (25,751)	$ (10,414)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic and diluted	$ (0.11)	$ (0.10)	$ (0.56)	$ (0.35)
Net loss per share attributable to PAVmed Inc. common stockholders - basic and diluted	$ (0.11)	$ (0.10)	$ (0.57)	$ (0.36)
Weighted average common shares outstanding, basic and diluted	48,380,677	31,030,929	45,563,961	29,211,694

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Dec. 31, 2018	$ 2,032	$ 27	$ 32,619	$ (36,993)	$ (161)	$ (2,476)
Balance, shares at Dec. 31, 2018	1,069,941	27,142,979
Issue common stock - registered offerings, net		$ 5	5,374			5,379
Issue common stock - registered offerings, net, shares		5,480,000
Issue common stock - upon partial conversions of Senior Secured Convertible Note		$ 4	4,156			4,160
Issue common stock - upon partial conversions of Senior Secured Convertible Note, shares		3,850,427
Series B Convertible Preferred Stock dividends declared	$ 196			(196)
Series B Convertible Preferred Stock dividends declared, shares	65,541
Issue common stock - Employee Stock Purchase Plan			67			67
Issue common stock - Employee Stock Purchase Plan, shares		82,772
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			1,024			1,024
Stock-based compensation - PAVmed Inc. 2014 Equity Plan, shares
Stock-based compensation - majority-owned subsidiary			11		142	153
Loss				(10,213)	(501)	(10,714)
Balance at Sep. 30, 2019	$ 2,228	$ 36	43,252	(47,403)	(520)	(2,407)
Balance, shares at Sep. 30, 2019	1,135,482	36,556,178
Balance at Jun. 30, 2019	$ 2,162	$ 34	40,519	(44,251)	(343)	(1,879)
Balance, shares at Jun. 30, 2019	1,113,201	34,139,220
Issue common stock - upon partial conversions of Senior Secured Convertible Note		$ 2	2,344			2,346
Issue common stock - upon partial conversions of Senior Secured Convertible Note, shares		2,334,186
Series B Convertible Preferred Stock dividends declared	$ 66			(66)
Series B Convertible Preferred Stock dividends declared, shares	22,281
Issue common stock - Employee Stock Purchase Plan			67			67
Issue common stock - Employee Stock Purchase Plan, shares		82,772
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			318			318
Stock-based compensation - PAVmed Inc. 2014 Equity Plan, shares
Stock-based compensation - majority-owned subsidiary			3		9	12
Loss				(3,085)	(186)	(3,271)
Balance at Sep. 30, 2019	$ 2,228	$ 36	43,252	(47,403)	(520)	(2,407)
Balance, shares at Sep. 30, 2019	1,135,482	36,556,178
Balance at Dec. 31, 2019	$ 2,296	$ 41	47,554	(53,715)	(814)	(4,638)
Balance, shares at Dec. 31, 2019	1,158,209	40,478,861
Issue common stock - upon partial conversions of Senior Secured Convertible Note		$ 8	14,667			14,675
Issue common stock - upon partial conversions of Senior Secured Convertible Note, shares		7,412,682
Series B Convertible Preferred Stock dividends declared	$ 210			(210)
Series B Convertible Preferred Stock dividends declared, shares	70,279
Issue common stock - Employee Stock Purchase Plan			356			356
Issue common stock - Employee Stock Purchase Plan, shares		306,555
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			1,409			1,409
Stock-based compensation - PAVmed Inc. 2014 Equity Plan, shares
Stock-based compensation - majority-owned subsidiary			10		39	49
Issue common stock - exercise Series S warrants		$ 1	11			12
Issue common stock - exercise Series S warrants, shares		1,199,383
Issue common stock - exercise Series Z warrants
Issue common stock - exercise Series Z warrants, shares		100
Issue common stock - conversion Series B Convertible Preferred Stock	$ (43)		43
Issue common stock - conversion Series B Convertible Preferred Stock, shares	(25,000)	25,000
Vesting of restricted stock awards
Vesting of restricted stock awards, shares		233,334
Issue common stock of majority- owned subsidiary exercise of stock options					5	5
Loss				(25,536)	(1,093)	(26,629)
Balance at Sep. 30, 2020	$ 2,463	$ 50	64,050	(79,461)	(1,863)	(14,761)
Balance, shares at Sep. 30, 2020	1,203,488	49,655,915
Balance at Jun. 30, 2020	$ 2,393	$ 48	60,147	(73,908)	(1,485)	(12,805)
Balance, shares at Jun. 30, 2020	1,179,872	47,919,386
Issue common stock - upon partial conversions of Senior Secured Convertible Note		$ 2	3,100			3,102
Issue common stock - upon partial conversions of Senior Secured Convertible Note, shares		1,584,140
Series B Convertible Preferred Stock dividends declared	$ 70			(70)
Series B Convertible Preferred Stock dividends declared, shares	23,616
Issue common stock - Employee Stock Purchase Plan			230			230
Issue common stock - Employee Stock Purchase Plan, shares		152,289
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			570			570
Stock-based compensation - PAVmed Inc. 2014 Equity Plan, shares
Stock-based compensation - majority-owned subsidiary			3		13	16
Issue common stock - exercise Series Z warrants
Issue common stock - exercise Series Z warrants, shares		100
Loss				(5,483)	(391)	(5,874)
Balance at Sep. 30, 2020	$ 2,463	$ 50	$ 64,050	$ (79,461)	$ (1,863)	$ (14,761)
Balance, shares at Sep. 30, 2020	1,203,488	49,655,915

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss - before noncontrolling interest ("NCI")	$ (26,629)	$ (10,714)
Adjustments to reconcile net loss - before NCI to net cash used in operating activities
Depreciation expense	17	10
Stock-based compensation	1,458	1,177
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note	5,521	341
Debt extinguishment loss - Senior Secured Convertible Notes	4,600	666
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,159)	(19)
Accounts payable	854	61
Accrued expenses and other current liabilities	152	(790)
Net cash flows used in operating activities	(15,186)	(9,267)
Cash flows from investing activities
Purchase of equipment	(47)	(25)
Net cash flows used in investing activities	(47)	(25)
Cash flows from financing activities
Proceeds - issue of Senior Secured Convertible Notes	13,300
Proceeds - issue of Senior Convertible Note	3,700
Proceeds - Cares Act Paycheck Protection Program Loan	300
Proceeds - issue of common stock - registered offerings		5,480
Payment - offering costs - registered offerings		(101)
Payment - Senior Secured Convertible Notes - non-installment payments	(366)	(279)
Proceeds - issue common stock - Employee Stock Purchase Plan	356	67
Proceeds - exercise of Series S Warrants	12
Proceeds - exercise of stock options issued under equity incentive plan of majority owned subsidiary	5
Net cash flows provided by financing activities	17,307	5,167
Net increase (decrease) in cash	2,074	(4,125)
Cash, beginning of period	6,219	8,222
Cash, end of period	$ 8,293	$ 4,098

The Company and Description of

The Company and Description of the Business	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Description of the Business	Note 1 — The Company and Description of the Business PAVmed Inc. (“PAVmed” or the “Company”) together with its majority owned subsidiaries, Lucid Diagnostics, Inc. (“Lucid Diagnostics” or “LUCID”) and Solys Diagnostics, Inc. (“Solys Diagnostics” or “SOLYS”) were organized to advance a broad pipeline of innovative medical technologies from concept to commercialization, employing a business model focused on capital efficiency and speed to market. The Company’s activities have focused on advancing the lead products towards regulatory approval and commercialization, protecting its intellectual property, and building its corporate infrastructure and management team. The Company operates in one segment as a medical device company. The ability of the Company to generate revenue depends upon the Company’s ability to successfully advance the commercialization of EsoGuard and CarpX while also completing the development and the necessary regulatory approvals of its other products and services. In this regard: ● EsoCheck has received 510(k) marketing clearance from the FDA as an esophageal cell collection device in June 2019; ● EsoGuard completed the certification required by the Clinical Laboratory Improvement Amendment (“CLIA”) and accreditation of the College of American Pathologists (“CAP”) making it commercially available as a Laboratory Developed Test (“LDT”) at LUCID’s contract diagnostic laboratory service provider in California in December 2019; and, ● CarpX, developed as a patented, single-use, disposable, minimally invasive device designed as a precision cutting tool to treat carpal tunnel syndrome while reducing recovery times, received 510(k) marketing clearance from the FDA in April 2020. Although the Company’s current operational activities are principally focused on the commercialization of EsoGuard and CarpX its development activities are focused on pursuing FDA approval and clearance of other lead products in our product portfolio pipeline, including EsoGuard IVD, PortIO, DisappEAR, NextFlo, and EsoCure. The Company has financed its operations principally through the public and private issuances of its common stock, preferred stock, warrants, and debt.

Financial Condition, Going Conc

Financial Condition, Going Concern and Management Plans	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Condition, Going Concern and Management Plans	Note 2 — Financial Condition, Going Concern and Management Plans The Company is subject to all of the risks and uncertainties typically faced by diagnostic and medical device companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing R&D and clinical trials. The Company expects to continue incurring losses for the foreseeable future. The Company’s existing liquidity is not sufficient to fund its operations, anticipated capital expenditures and working capital funding until the Company reaches significant revenues. As such, the Company intends to rely on capital markets to obtain additional equity or debt financing, especially if the Company experiences downturns in its business that are more severe or longer than anticipated, or if the Company experiences significant increases in expense levels resulting from being a publicly-traded company or from expansion of operations. If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all. As a result of recurring operating losses and net operating cash flow deficits there is substantial doubt about the Company’s ability to continue as a going concern within one year from the date of this filing. The unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Significant Accounting Policies Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2020. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc. and Solys Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the respective minority ownership interest of each respective entity. The condensed consolidated balance sheet as of December 31, 2019, which has been derived from audited consolidated financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s consolidated financial information. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related consolidated financial information should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on April 14, 2020. All amounts in these accompanying notes to the accompanying unaudited condensed consolidated financial statements are presented in thousands, if not otherwise noted as being presented in millions, except for shares and per share amounts. Use of Estimates In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements and estimating the fair value of financial instruments recorded as liabilities. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Recent Accounting Standards Adoption of new accounting Standard On January 1, 2020, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standard Update (“ASU”) 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, On January 1, 2020, the Company adopted ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606” In August 2020, the FASB issued its Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 — Related Party Transactions Previously, in May 2018, Lucid Diagnostics Inc., a majority-owned subsidiary of the Company: entered into a patent license agreement with Case Western Reserve University (“CWRU”), referred to as the “EsoGuard™ License Agreement”, which provides for the exclusive worldwide license of the intellectual property rights for the proprietary technologies collectively referred to as the “EsoGuard Technology”; issued 943,464 shares of its common stock to CWRU and 289,679 shares of its common stock to each of the three Physician Inventors of the EsoGuard Technology, for a purchase price of $0.001 per share; entered into consulting agreements with each of the three Physician Inventors; and, each of the three Physician Inventors were granted stock options under the Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan and the PAVmed Inc. 2014 Long-Term Incentive Equity Plan, as such plans are discussed in Note 6, Stock-Based Compensation During the three and nine months ended September 30, 2020 and 2019 the Company incurred the following expenses with respect to the minority shareholders of Lucid Diagnostics Inc: For the three months ended September 30, For the nine months ended September 30, 2020 2019 2020 2019 Reimbursement - CWRU patent legal fees $ 79 $ 20 $ 138 $ 98 EsoCheck devices provided to CWRU — — 15 — EsoGuard Technology Physician Inventors’ consulting agreements fees 20 24 74 98 EsoGuard Technology Physician Inventors’ stock based compensation expense 6 3 17 51 Total $ 105 $ 47 $ 244 $ 247 As of September 30, 2020 the Company has payables of $20 for such related party transactions.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	Note 5 — Commitment and Contingencies Rental Agreements - Office Space Total rent expense incurred under short-term and /or month-to-month rental agreements for office space was $46 and $34, for the three months ended September 30, 2020 and 2019, respectively, and $145 and $98, for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020, the Company’s minimum lease payments for such office space rental agreements are estimated to be a total of approximately $158 for the period October 1, 2020 to September 30, 2021.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 6 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan - Stock Options Stock options issued and outstanding under the PAVmed Inc. 2014 Long-Term Incentive Equity Plan (“PAVmed Inc. 2014 Equity Plan”) for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 5,203,529 $ 2.68 8.1 Granted 1,470,000 $ 2.16 Exercised — $ — Forfeited — $ — Outstanding stock options at September 30, 2020 6,673,529 $ 2.58 7.5 Vested and exercisable stock options at September 30, 2020 4,430,981 $ 3.00 6.7 The aggregate intrinsic value of stock options granted under the PAVmed Inc. 2014 Equity as of September 30, 2020 was $1,598 with respect to stock options outstanding and $922 with respect to such stock options vested and exercisable. The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on September 30, 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price. As noted, in the nine months ended September 30, 2020, a total of 1,470,000 stock options were granted under the PAVmed Inc. 2014 Equity Plan, with each such stock option grant having a ten year contractual term from date-of-grant, vesting ratably over twelve quarters commencing with the grant date quarter, and a weighted average exercise price of $2.16 per share of common stock of PAVmed Inc. Subsequent to September 30, 2020, a total of 200,000 stock options were granted under the PAVmed Inc. 2014 Equity Plan, with each such stock option grant having a ten year contractual term from date-of-grant, vesting ratably over twelve quarters commencing with the grant date quarter, and a weighted average exercise price of $1.84 per share of common stock of PAVmed Inc. PAVmed Inc. 2014 Long-Term Incentive Equity Plan - Restricted Stock Awards On March 15, 2019, a total of 700,000 restricted stock awards were granted to employees under the PAVmed Inc. 2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of March 15, 2020. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. On March 15, 2020, approximately 233,334 of such restricted stock awards vested. On May 1, 2020, a total of 950,000 restricted stock awards were granted to employees under the PAVmed Inc. 2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of May 1, 2021. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. At the Company’s annual meeting of stockholders on July 24, 2020, the Company’s stockholders approved an increase to the share reservation of the PAVmed Inc. 2014 Equity Plan of an additional 2,000,000 shares of common stock of the Company, from 7,951,081 shares to 9,951,081 shares. PAVmed Inc. Employee Stock Purchase Plan (“ESPP”) The PAVmed Inc. Employee Stock Purchase Plan (“ESPP”) provides eligible employees the opportunity to purchase shares of PAVmed Inc. common stock through payroll deductions during six month periods, wherein the purchase price per share of common stock is the lower of 85% of the quoted closing price per share of PAVmed Inc. common stock at the beginning or end of each six month share purchase period. The PAVmed Inc. ESPP share purchase dates are March 31 and September 30. On the March 31, 2020 ESPP purchase date, 154,266 shares of PAVmed Inc. common stock were issued for proceeds of approximately $125; and on the September 30, 2020 ESPP purchase date, 152,289 shares of PAVmed Inc. common stock were issued for proceeds of approximately $231. At the Company’s annual meeting of stockholders on July 24, 2020, the Company’s stockholders approved an increase to the share reservation of the PAVmed Inc. ESPP of an additional 500,000 shares of common stock of the Company, from 250,000 shares to 750,000 shares. Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan - Stock Options The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics Inc. 2018 Equity Plan”) is separate and apart from the PAVmed Inc. 2014 Equity Plan discussed above. Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 995,000 $ 0.86 9.0 Granted — $ — Exercised (3,333 ) $ 1.50 Forfeited — $ — Outstanding stock options at September 30, 2020 991,667 $ 0.86 8.2 Vested and exercisable stock options at September 30, 2020 706,242 $ 0.83 8.1 Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan, have a ten-year contractual term from date of grant, and vest ratably over twelve successive calendar quarters, with first vesting date in the quarter of the date of grant. During the nine months ended September 30, 2020, 3,333 stock options issued under the Lucid Diagnostics Inc. 2018 Equity Plan were exercised for cash proceeds of $5, resulting in the issue of a corresponding number of shares of common stock of Lucid Diagnostics Inc. Stock-Based Compensation Expense The consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 General and administrative expenses $ 448 $ 269 $ 1,132 $ 853 Research and development expenses 138 61 326 324 Total $ 586 $ 330 $ 1,458 $ 1,177 As of September 30, 2020, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, as discussed above, is as follows: Unrecognized Weighted Average PAVmed Inc. 2014 Equity Plan Stock Options $ 2,075 1.0 years Restricted Stock Awards $ 2,019 2.4 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 62 1.1 years The stock options granted under the PAVmed Inc. 2014 Equity Plan during the nine months ended September 30, 2020 and 2019, had a weighted average estimated fair value of $1.28 per share and $0.48 per share, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2020 2019 Expected term of stock options (in years) 5.8 5.7 Expected stock price volatility 73 % 50 % Risk free interest rate 0.5 % 2.4 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan to non-employees under the previous provisions of FASB ASC 505-50 in the prior year nine months ended September 30, 2019, was based on a weighted average estimated fair value of such stock options of $1.87 per share, calculated using Black-Scholes valuation model weighted-average assumptions of an 8.6 year contractual term, a 60% expected stock price volatility, a 2.2% risk free interest rate, and a 0% expected dividend rate. The restricted stock awards granted to employees under the PAVmed Inc. 2014 Equity Plan are measured at their grant date estimated fair value based on the date-of-grant quoted price per share of PAVmed Inc. common stock. The 700,000 restricted stock awards granted on March 15, 2019 had an aggregate fair value of approximately $742 with such stock-based compensation expense recognized ratably over the requisite service period, which is the three-year vesting period as discussed above. The 950,000 restricted stock awards granted on May 1, 2020 had an aggregate fair value of approximately $1,938 with such stock-based compensation expense recognized ratably over the requisite service period, which is the three-year vesting period as discussed above. The stock-based compensation expense recognized in general and administrative expense related to restricted stock awards was approximately $185 and $62 in the three months ended September 30, 2020 and 2019, respectively, and $391 and $144 in the nine months ended September 30, 2020 and 2019, respectively. The stock-based compensation expense recognized in research and development expense related to restricted stock awards was $39 and $64 in the three and nine months ended September 30, 2020, respectively. Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.30 per share and $0.36 per share during the nine months ended September 30, 2020 and 2019, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2020 2019 Expected term of stock options (in years) 5.2 6.0 Expected stock price volatility 60 % 62 % Risk free interest rate 1.9 % 2.0 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan to non-employees under the previous provisions of FASB ASC 505-50 in the prior year nine months ended September 30, 2019, was based on a weighted average estimated fair value of such stock options of $0.36 per share, calculated using Black-Scholes valuation model weighted-average assumptions of a 6.0 year contractual term, a 62% expected stock price volatility, a 2.0% risk free interest rate, and a 0% expected dividend rate. The Company uses the Black-Scholes valuation model to estimate the fair value of stock options granted under both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, which requires the Company to make certain estimates and assumptions, with the weighted-average valuation assumptions for stock-based awards, principally as follows: ● The expected term of stock options represents the period of time stock options are expected to be outstanding, which is the expected term derived using the simplified method and, through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term; ● With respect to stock options granted under the PAVmed Inc. 2014 Equity Plan, the expected stock price volatility is based on the historical stock price volatility of PAVmed Inc. common stock (“PAVM”) and the volatilities of similar entities within the medical device industry over the period commensurate with the expected term, and through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term of the respective stock option; and, with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan, the expected stock price volatility is based on the historical stock price volatilities of similar entities within the medical device industry over the period commensurate with the expected term, and through December 31, 2019 for non-employees (under the previous provisions FASB ASC 505-50), was the remaining contractual term of the respective stock option; ● The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period commensurate with the expected term of the stock option; and, ● The expected dividend yield is based on annual dividends of $0.00 as there has not been a dividend paid to-date, and there is no plan to pay dividends for the foreseeable future. The price per share of PAVmed Inc. common stock used in the computation of estimated fair value of stock options granted under the PAVmed Inc. 2014 Equity Plan is its quoted closing price per share. The price per share of Lucid Diagnostics Inc. common stock used in the computation of estimated fair value of stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was estimated using a discounted cash flow method applied to a multi-year forecast of its future cash flows.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 7 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total September 30, 2020 Senior Secured Convertible Note - November 2019 $ — $ — $ 6,900 $ 6,900 Senior Convertible Note - April 2020 $ — $ — $ 4,600 $ 4,600 Senior Secured Convertible Note – August 2020 $ — $ — $ 8,720 $ 8,720 Totals $ — $ — $ 20,220 $ 20,220 December 31, 2019 Senior Secured Convertible Note - December 2018 $ — $ — $ 1,700 $ 1,700 Senior Secured Convertible Note - November 2019 $ — $ — $ 6,439 $ 6,439 Totals $ — $ — $ 8,139 $ 8,139 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the nine-month period ended September 30, 2020. The August 2020 Senior Secured Convertible Note, the April 2020 Senior Convertible Note, the November 2019 Senior Secured Convertible Notes and the December 2018 Senior Secured Convertible Note are each accounted for under the ASC 825-10-15-4 fair value option (“FVO”) election. Under the FVO election the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. As provided for by ASC 825-10-50-30(b), the estimated fair value adjustment is presented as a single line item within other income (expense) in the accompanying unaudited condensed consolidated statement of operations. Additional information on the changes in Level 3 liabilities measured at fair value for the three and nine-month periods ended September 30, 2020 and 2019, please see Note 8 – “Outstanding Debt.” The estimated fair value of financial instruments classified within the Level 3 category was determined using both observable inputs and unobservable inputs. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs. Fair Value Assumptions – September 30, 2020: November 2019 April 2020 August 2020 Required rate of return 0.12 % 65 % 40 % Conversion Price $ 1.60 $ 5.00 $ 5.00 Expected term (years) 0.79 1.58 1.85 Volatility 70 % 65 % 65 % Risk free rate 0.12 % 0.13 % 0.13 % Dividend yield 0 % 0 % 0 % Fair Value Assumptions – September 30, 2019: December 2018 Required rate of return 11.1 % Conversion Price $ 1.60 Expected term (years) 1.51 Volatility 53 % Risk free rate 1.8 % Dividend yield 0 %

Outstanding Debt

Outstanding Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Outstanding Debt	Note 8 — Outstanding Debt The fair value and face value principal of outstanding debt as of the dates indicated is as follows: Contractual Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value December 2018 Senior Secured Convertible Note (1) December 31, 2020 7.875 % $ 1.60 $ — $ — November 2019 Senior Secured Convertible Note (2) September 30, 2021 7.875 % $ 1.60 $ 6,006 $ 6,900 April 2020 Senior Convertible Note (3) April 30, 2022 7.875 % $ 5.00 $ 4,111 $ 4,600 August 2020 Senior Secured (4) August 6, 2022 7.875 % $ 5.00 $ 7,750 $ 8,720 Balance as of September 30, 2020 $ 17,867 $ 20,220 December 2018 Senior Secured Convertible Note (1) December 31, 2020 7.875 % $ 1.60 $ 1,692 $ 1,700 November 2019 Senior Secured Convertible Note (2) September 30, 2021 7.875 % $ 1.60 $ 7,000 $ 6,439 Balance as of December 31, 2019 $ 8,692 $ 8,139 (1) With respect to the December 2018 Senior Secured Convertible Note, in the nine months ended September 30, 2020, approximately $1,692 of principal repayments and approximately $6 of non-installment payments were settled through the issuance of 2,075,198 shares of the Company’s common stock with a fair value of approximately $2,901 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). The December 2018 Senior Secured Convertible Debt was paid in full as of June 4, 2020. (2) With respect to the November 2019 Senior Secured Convertible Note - Series A and Series B - in the nine months ended September 30, 2020, approximately $7,993 of Accelerated and Bi-Monthly Installment principal repayments and approximately $383 of non-installment payments were settled through the issuance of 5,337,484 shares of the Company’s common stock with a fair value of approximately $11,774 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Subsequent to September 30, 2020, through November 4, 2020, approximately $1,720 of Accelerated and Bi-Monthly Installment principal repayments along with approximately $28 of corresponding non-installment payments were settled through the issuance of 1,182,266 shares of the Company’s common stock with a fair value of approximately $2,266 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). The November 2019 Senior Secured Convertible Note - Series B has a face value principal of approximately $7,000 and lender fees of approximately $700 (recognized as a current period other expense), resulting in cash proceeds of approximately $6,300 received by the Company, with such cash proceeds delivered to the Company by the investors on March 30, 2020, at their election under the prepayment provisions of the Series B note of the November 2019 Senior Secured Convertible Note. The November 2019 Senior Secured Convertible Notes - Series A and Series B - have a stated interest rate of 7.875% per annum to the extent the investor has funded the cash proceeds of each such respective Series A and Series B. During the period November 4, 2019 to March 29, 2020, during which period the Series B was not funded by the investor, the Company incurred interest expense of 3.0% per annum on the Series B $7.0 million face value principal. The (cash) payment of such 3.0% interest on the $7.0 million face value principal resulted in the recognition of approximately $53 of interest expense during the period January 1, 2020 through March 29, 2020, with such interest expense included in other income (expense) in the accompanying (unaudited) condensed consolidated statement of operations for the nine months ended September 30, 2020. (3) On April 30, 2020, the Company entered into a Security Purchase Agreement for the issue of a Senior Convertible Note with a face value principal of approximately $4,111 and lender fees of approximately $411 (recognized as a current period other expense), resulting in $3,700 cash proceeds received by the Company. - referred to as the April 2020 Senior Convertible Note. Additionally, under a separate agreement, the Company incurred a current period expense of approximately $120 with respect to the placement agent advisory fee. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon. (4) The Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor (the “Investor”), and pursuant to the SPA, on August 6, 2020, the Company issued to the Investor a Senior Secured Convertible Note (the “August 2020 Senior Secured Convertible Note”) with a face value principal amount of $7,750 and $750 lender fee (recognized as a current period other expense), resulting in $7,000 cash proceeds received by the Company. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon The August 2020 Senior Secured Convertible Note investor and its affiliates also hold the Company’s November 2019 Senior Secured Convertible Notes the April 2020 Senior Convertible Note. The August 2020 Senior Secured Convertible Note contains certain representations and warranties, covenants and indemnities for similar transactions as well as the past transactions entered into with the investor. The August 2020 Senior Secured Convertible Note contains certain redemption rights similar to the April 2020 Senior Convertible Note and security interest with a first priority line in all of our assets, including all of the Company’ current and future significant subsidiaries, similar to the November 2019 Senior Secured Convertible Notes. Subsequent to September 30, 2020, effective November 6, 2020, the Company entered into a waiver agreement with the holder of the April 2020 Senior Convertible Note and the August 2020 Senior Secured Convertible Note. Prior to the waiver agreement, the noteholder had the right, at any time from and after October 30, 2020, in its sole discretion, to require the Company to redeem all, or any portion, of the respective convertible notes. Under the waiver agreement, so long as no event of default has occurred and is continuing under the convertible notes (unless waived in writing by the holder of the convertible notes), the noteholder waived this redemption right until November 30, 2020. Furthermore, the waiver will be automatically extended for additional one-month periods, unless the noteholder delivers notice to the Company of an election to terminate the waiver prior to the then-current end date for the waiver. The changes in the fair value of debt during the three and nine months ended September 30, 2020 is as follows: December 2018 Senior Secured Convertible Note November 2019 Senior Secured Convertible Note Series A & Series B April 2020 Senior Convertible Note August 2020 Senior Secured Convertible Note Sum of Balance Sheet Fair Value Components Other Income (Expense) Fair Value - December 31, 2019 $ 1,700 $ 6,439 $ — $ — $ 8,139 Face value principal – issue date — 7,000 — — 7,000 Fair value adjustment – issue date — 2,600 — — 2,600 $ (2,600 ) Installment repayments – common stock (1,642 ) — — — (1,642 ) Non-installment payments – common stock (4 ) — — — (4 ) Non-installment payments – cash — (138 ) — — (138 ) Change in fair value 9 4,699 — — 4,708 (4,708 ) Lender Fee - November 2019 Senior Secured Convertible Note - Series B — — — — — (700 ) Fair Value at March 31, 2020 $ 63 $ 20,600 — $ — $ 20,663 Other Income (Expense) - Change in fair value - three months ended March 31, 2020 $ (8,008 ) Face value principal – issue date — — 4,111 — 4,111 Fair value adjustment – issue date — — (411 ) — (411 ) 411 Installment repayments – common stock (50 ) (5,695 ) — — (5,745 ) Non-installment payments – common stock (2 ) (242 ) — — (244 ) Non-installment payments – cash — — (54 ) — (54 ) Change in fair value (11 ) (2,363 ) 254 — (2,120 ) 2,120 Lender Fee - April 2020 Senior Convertible Note — — — — — (411 ) Fair Value at June 30, 2020 $ — $ 12,300 3,900 $ — $ 16,200 Other Income (Expense) - Change in fair value - three months ended June 30, 2020 $ 2,120 Face value principal – issue date — — — 7,750 7,750 Fair value adjustment – issue date — — — (750 ) (750 ) 750 Installment repayments – common stock — (2,298 ) — — (2,298 ) Non-installment payments – common stock — (141 ) — — (141 ) Non-installment payments – cash — — (81 ) (93 ) (174 ) Change in fair value — (2,961 ) 781 1,813 (367 ) 367 Lender Fee - August 2020 Senior Secured Convertible Note — — — — — (750 ) Fair Value at September 30, 2020 $ — $ 6,900 $ 4,600 $ 8,720 $ 20,220 Other Income (Expense) - Change in fair value - three months ended September 30, 2020 $ 367 Other Income (Expense) - Change in fair value - nine months ended September 30, 2020 $ (5,520 ) The changes in the fair value of debt during the three and nine months ended September 30, 2019 is as follows: December 2018 Senior Secured Convertible Note Other Income (Expense) Fair Value - December 31, 2018 $ 7,903 Installment repayments - common stock (52 ) Non-installment payments - common stock — Non-installment payments - cash (159 ) Change in fair value 559 $ (559 ) Fair Value - March 31, 2019 $ 8,251 Other Income (Expense) - Change in fair value $ (559 ) Installment repayments - common stock (1,480 ) Non-installment payments - common stock (22 ) Non-installment payments - cash (120 ) Change in fair value 161 $ (161 ) Fair Value - June 30, 2019 $ 6,790 Other Income (Expense) - Change in fair value $ (161 ) Installment repayments - common stock (1,850 ) Non-Installment repayments – common stock (90 ) Non-installment payments – cash — Change in fair value (379 ) $ 379 Fair Value - September 30, 2019 $ 4,472 Other Income (Expense) - Change in fair value – three months ended $ 379 Other Income (Expense) - Change in fair value - nine months ended September 30, 2019 $ (341 )

Cares Act Paycheck Protection P

Cares Act Paycheck Protection Program Loan	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Table]
Cares Act Paycheck Protection Program Loan	Note 9 — Cares Act Paycheck Protection Program Loan On April 8, 2020 the Company entered into a loan agreement with JP Morgan Chase, N.A., and received approximately $300 of proceeds, pursuant to the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) Paycheck Protection Program (“PPP”) - the “PPP Loan”. The PPP Loan matures on April 8, 2022 and bears interest at a rate of approximately 1.0% per annum. Monthly amortized principle and interest payments are deferred for six months after the PPP Loan date-of-disbursement after which time each month following the deferral period, the Company will make equal monthly payments on principal and interest balances to fully amortize the loan balances by the maturity date. As such, $200 is presented as a current liability and $100 is presented as a non-current liability in the accompanying unaudited condensed consolidated balance sheet as of September 30, 2020. The PPP Loan funds were received on April 8, 2020. The PPP Loan contains events of default and other provisions customary for a loan of this type. The Paycheck Protection Program provides that (1) the use of PPP Loan amount shall be limited to certain qualifying expenses, (2) 100 per cent of the principal amount of the loan is guaranteed by the Small Business Administration and (3) an amount up to the full principal amount may qualify for loan forgiveness in accordance with the terms of CARES Act. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during either, at our discretion, the eight-week period or twenty-four week period beginning on the date of disbursement of proceeds from the PPP loan. In the event the PPP loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. The Company is not yet able to determine the amount potentially to be forgiven, if any. As of September 30, 2020 and the date of this filing, the Company was in full compliance with the provisions of the PPP Loan.

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Preferred Stock	Note 10 — Preferred Stock The Company is authorized to issue 20 million shares of its preferred stock, par value of $0.001 per share, with such designation, rights, and preferences as may be determined by the Company’s board of directors. There were 1,203,488 and 1,158,209 shares of Series B Convertible Preferred Stock (classified in permanent equity) issued and outstanding as of September 30, 2020 and December 31, 2019, respectively. During the nine months ended September 30, 2020, the Company’s board-of-directors declared an aggregate of approximately $211 of Series B Convertible Preferred Stock dividends, earned as of December 31, 2019, March 31, 2020 and June 30, 2020, which have been settled by the issue of an additional aggregate 70,279 shares of Series B Convertible Preferred Stock. Subsequent to September 30, 2020, in October 2020, the Company’s board-of-directors declared a Series B Convertible Preferred Stock dividend earned as of September 30, 2020 and payable as of October 1, 2020, of approximately $74 to be settled by the issue of an additional 24,587 shares of Series B Convertible Preferred Stock (with such dividend not recognized as a dividend payable liability in the accompanying unaudited condensed consolidated balance sheet as the Company’s board of directors had not declared such dividends payable as of September 30, 2020).

Stockholders' Equity, Common St

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest	Note 11 — Stockholders’ Equity, Common Stock Purchase Warrants, and Noncontrolling Interest The Company is authorized to issue up to 150 million shares of its common stock, par value of $0.001 per share, inclusive of an increase of 50 million shares approved by the Company’s stockholders at their July 24, 2020 annual meeting. There were 49,655,951 and 40,478,861 shares of common stock issued and outstanding as of September 30, 2020 and December 31, 2019, respectively. The following table summarizes outstanding warrants to purchase common stock of the Company (classified in permanent equity) at the dates indicated: Common Stock Purchase Warrants Issued and Outstanding at Weighted Weighted Average Average September 30, Exercise December 31, Exercise Expiration 2020 Price /Share 2019 Price Date Series Z Warrants 16,814,939 $ 1.60 16,815,039 $ 1.60 April 2024 UPO - Series Z Warrants 53,000 $ 1.60 53,000 $ 1.60 January 2022 Series W Warrants 381,818 $ 5.00 381,818 $ 5.00 January 2022 Series S Warrants — $ — 1,199,383 $ 0.01 June 2032 Total 17,249,757 $ 1.68 18,449,240 $ 1.57 In the nine months ended September 30, 2020, 1,199,383 Series S Warrants and 100 Series Z Warrants were exercised for cash at their respective exercise price per share, resulting in the issuance of a corresponding number of shares of the Company’s common stock. The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is with respect to the Company’s majority-owned subsidiaries Lucid Diagnostics Inc. and Solys Diagnostics Inc., summarized for the periods indicated as follows: Nine Months Ended Year Ended NCI - equity (deficit) - beginning of period $ (814 ) $ (161 ) Minority Interest investment in Solys Diagnostics Inc. — 889 Minority Interest share subscription receivable - Solys Diagnostics Inc. — (889 ) Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise 5 — Net loss attributable to NCI - Lucid Diagnostics Inc. (1,007 ) (801 ) Net loss attributable to NCI - Solys Diagnostics Inc. (86 ) (10 ) Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 39 158 NCI - equity (deficit) - end of period $ (1,863 ) $ (814 )

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Loss Per Share	Note 12 — Loss Per Share Basic earnings (loss) per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per common share is computed similar to basic earnings (loss) per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Diluted weighted average common shares include common stock potentially issuable under the Company’s convertible notes, preferred stock, warrants and vested and unvested stock options. The following table sets forth the computation of earnings (loss) per share attributable to PAVmed Inc. and loss per share attributable to PAVmed Inc. common stockholders for the respective periods indicated: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Numerator Net loss - before noncontrolling interest $ (5,874 ) $ (3,271 ) $ (26,629 ) $ (10,714 ) Net loss attributable to noncontrolling interest 391 186 1,093 501 Net loss - as reported, attributable to PAVmed Inc. $ (5,483 ) $ (3,085 ) $ (25,536 ) $ (10,213 ) Series B Convertible Preferred Stock dividends: $ (74 ) $ (68 ) $ (215 ) $ (201 ) Net loss attributable to PAVmed Inc. common stockholders $ (5,557 ) $ (3,153 ) $ (25,751 ) $ (10,414 ) Denominator Weighted average common shares outstanding, basic and diluted 48,380,677 31,030,929 45,563,961 29,211,694 Loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.11 ) $ (0.10 ) $ (0.56 ) $ (0.35 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.11 ) $ (0.10 ) $ (0.57 ) $ (0.36 ) The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: September 30, 2020 2019 PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards 8,090,195 5,853,529 Unit purchase options - as to shares of common stock 53,000 53,000 Unit purchase options - as to shares underlying Series Z Warrants 53,000 53,000 Series Z Warrants 16,814,939 16,815,039 Series W Warrants 381,818 381,818 Series B Convertible Preferred Stock 1,203,488 1,135,482 Total 26,596,440 24,291,868

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 14, 2020.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc. and Solys Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity, including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the respective minority ownership interest of each respective entity. The condensed consolidated balance sheet as of December 31, 2019, which has been derived from audited consolidated financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements at such date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s consolidated financial information. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related consolidated financial information should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on April 14, 2020. All amounts in these accompanying notes to the accompanying unaudited condensed consolidated financial statements are presented in thousands, if not otherwise noted as being presented in millions, except for shares and per share amounts.
Use of Estimates	Use of Estimates In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements and estimating the fair value of financial instruments recorded as liabilities. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.
Recent Accounting Standards	Recent Accounting Standards Adoption of new accounting Standard On January 1, 2020, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standard Update (“ASU”) 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, On January 1, 2020, the Company adopted ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606” In August 2020, the FASB issued its Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Schedule of Incurred Expenses of Minority Shareholders	During the three and nine months ended September 30, 2020 and 2019 the Company incurred the following expenses with respect to the minority shareholders of Lucid Diagnostics Inc: For the three months ended September 30, For the nine months ended September 30, 2020 2019 2020 2019 Reimbursement - CWRU patent legal fees $ 79 $ 20 $ 138 $ 98 EsoCheck devices provided to CWRU — — 15 — EsoGuard Technology Physician Inventors’ consulting agreements fees 20 24 74 98 EsoGuard Technology Physician Inventors’ stock based compensation expense 6 3 17 51 Total $ 105 $ 47 $ 244 $ 247

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Summarizes Information About Stock Options	Stock options issued and outstanding under the PAVmed Inc. 2014 Long-Term Incentive Equity Plan (“PAVmed Inc. 2014 Equity Plan”) for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 5,203,529 $ 2.68 8.1 Granted 1,470,000 $ 2.16 Exercised — $ — Forfeited — $ — Outstanding stock options at September 30, 2020 6,673,529 $ 2.58 7.5 Vested and exercisable stock options at September 30, 2020 4,430,981 $ 3.00 6.7 Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period noted is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2019 995,000 $ 0.86 9.0 Granted — $ — Exercised (3,333 ) $ 1.50 Forfeited — $ — Outstanding stock options at September 30, 2020 991,667 $ 0.86 8.2 Vested and exercisable stock options at September 30, 2020 706,242 $ 0.83 8.1
Schedule of Stock-Based Compensation Awards Granted	The consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 General and administrative expenses $ 448 $ 269 $ 1,132 $ 853 Research and development expenses 138 61 326 324 Total $ 586 $ 330 $ 1,458 $ 1,177
Schedule of Unrecognized Compensation Expense	As of September 30, 2020, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, as discussed above, is as follows: Unrecognized Weighted Average PAVmed Inc. 2014 Equity Plan Stock Options $ 2,075 1.0 years Restricted Stock Awards $ 2,019 2.4 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 62 1.1 years
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	The stock options granted under the PAVmed Inc. 2014 Equity Plan during the nine months ended September 30, 2020 and 2019, had a weighted average estimated fair value of $1.28 per share and $0.48 per share, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2020 2019 Expected term of stock options (in years) 5.8 5.7 Expected stock price volatility 73 % 50 % Risk free interest rate 0.5 % 2.4 % Expected dividend yield 0 % 0 % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $0.30 per share and $0.36 per share during the nine months ended September 30, 2020 and 2019, respectively, and was calculated using the following weighted average Black-Scholes valuation model assumptions: Nine Months Ended September 30, 2020 2019 Expected term of stock options (in years) 5.2 6.0 Expected stock price volatility 60 % 62 % Risk free interest rate 1.9 % 2.0 % Expected dividend yield 0 % 0 %

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the periods indicated is as follows: Fair Value Measurement on a Recurring Basis at (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total September 30, 2020 Senior Secured Convertible Note - November 2019 $ — $ — $ 6,900 $ 6,900 Senior Convertible Note - April 2020 $ — $ — $ 4,600 $ 4,600 Senior Secured Convertible Note – August 2020 $ — $ — $ 8,720 $ 8,720 Totals $ — $ — $ 20,220 $ 20,220 December 31, 2019 Senior Secured Convertible Note - December 2018 $ — $ — $ 1,700 $ 1,700 Senior Secured Convertible Note - November 2019 $ — $ — $ 6,439 $ 6,439 Totals $ — $ — $ 8,139 $ 8,139 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the nine-month period ended September 30, 2020.
Schedule of Fair Value Assumption Used	Fair Value Assumptions – September 30, 2020: November 2019 April 2020 August 2020 Required rate of return 0.12 % 65 % 40 % Conversion Price $ 1.60 $ 5.00 $ 5.00 Expected term (years) 0.79 1.58 1.85 Volatility 70 % 65 % 65 % Risk free rate 0.12 % 0.13 % 0.13 % Dividend yield 0 % 0 % 0 % Fair Value Assumptions – September 30, 2019: December 2018 Required rate of return 11.1 % Conversion Price $ 1.60 Expected term (years) 1.51 Volatility 53 % Risk free rate 1.8 % Dividend yield 0 %

Outstanding Debt (Tables)

Outstanding Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Summary of Outstanding Debt	The fair value and face value principal of outstanding debt as of the dates indicated is as follows: Contractual Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value December 2018 Senior Secured Convertible Note (1) December 31, 2020 7.875 % $ 1.60 $ — $ — November 2019 Senior Secured Convertible Note (2) September 30, 2021 7.875 % $ 1.60 $ 6,006 $ 6,900 April 2020 Senior Convertible Note (3) April 30, 2022 7.875 % $ 5.00 $ 4,111 $ 4,600 August 2020 Senior Secured (4) August 6, 2022 7.875 % $ 5.00 $ 7,750 $ 8,720 Balance as of September 30, 2020 $ 17,867 $ 20,220 December 2018 Senior Secured Convertible Note (1) December 31, 2020 7.875 % $ 1.60 $ 1,692 $ 1,700 November 2019 Senior Secured Convertible Note (2) September 30, 2021 7.875 % $ 1.60 $ 7,000 $ 6,439 Balance as of December 31, 2019 $ 8,692 $ 8,139 (1) With respect to the December 2018 Senior Secured Convertible Note, in the nine months ended September 30, 2020, approximately $1,692 of principal repayments and approximately $6 of non-installment payments were settled through the issuance of 2,075,198 shares of the Company’s common stock with a fair value of approximately $2,901 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). The December 2018 Senior Secured Convertible Debt was paid in full as of June 4, 2020. (2) With respect to the November 2019 Senior Secured Convertible Note - Series A and Series B - in the nine months ended September 30, 2020, approximately $7,993 of Accelerated and Bi-Monthly Installment principal repayments and approximately $383 of non-installment payments were settled through the issuance of 5,337,484 shares of the Company’s common stock with a fair value of approximately $11,774 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Subsequent to September 30, 2020, through November 4, 2020, approximately $1,720 of Accelerated and Bi-Monthly Installment principal repayments along with approximately $28 of corresponding non-installment payments were settled through the issuance of 1,182,266 shares of the Company’s common stock with a fair value of approximately $2,266 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). The November 2019 Senior Secured Convertible Note - Series B has a face value principal of approximately $7,000 and lender fees of approximately $700 (recognized as a current period other expense), resulting in cash proceeds of approximately $6,300 received by the Company, with such cash proceeds delivered to the Company by the investors on March 30, 2020, at their election under the prepayment provisions of the Series B note of the November 2019 Senior Secured Convertible Note. The November 2019 Senior Secured Convertible Notes - Series A and Series B - have a stated interest rate of 7.875% per annum to the extent the investor has funded the cash proceeds of each such respective Series A and Series B. During the period November 4, 2019 to March 29, 2020, during which period the Series B was not funded by the investor, the Company incurred interest expense of 3.0% per annum on the Series B $7.0 million face value principal. The (cash) payment of such 3.0% interest on the $7.0 million face value principal resulted in the recognition of approximately $53 of interest expense during the period January 1, 2020 through March 29, 2020, with such interest expense included in other income (expense) in the accompanying (unaudited) condensed consolidated statement of operations for the nine months ended September 30, 2020. (3) On April 30, 2020, the Company entered into a Security Purchase Agreement for the issue of a Senior Convertible Note with a face value principal of approximately $4,111 and lender fees of approximately $411 (recognized as a current period other expense), resulting in $3,700 cash proceeds received by the Company. - referred to as the April 2020 Senior Convertible Note. Additionally, under a separate agreement, the Company incurred a current period expense of approximately $120 with respect to the placement agent advisory fee. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon. (4) The Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor (the “Investor”), and pursuant to the SPA, on August 6, 2020, the Company issued to the Investor a Senior Secured Convertible Note (the “August 2020 Senior Secured Convertible Note”) with a face value principal amount of $7,750 and $750 lender fee (recognized as a current period other expense), resulting in $7,000 cash proceeds received by the Company. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon
Schedule of Senior Convertible Note Estimated Fair Value	The changes in the fair value of debt during the three and nine months ended September 30, 2020 is as follows: December 2018 Senior Secured Convertible Note November 2019 Senior Secured Convertible Note Series A & Series B April 2020 Senior Convertible Note August 2020 Senior Secured Convertible Note Sum of Balance Sheet Fair Value Components Other Income (Expense) Fair Value - December 31, 2019 $ 1,700 $ 6,439 $ — $ — $ 8,139 Face value principal – issue date — 7,000 — — 7,000 Fair value adjustment – issue date — 2,600 — — 2,600 $ (2,600 ) Installment repayments – common stock (1,642 ) — — — (1,642 ) Non-installment payments – common stock (4 ) — — — (4 ) Non-installment payments – cash — (138 ) — — (138 ) Change in fair value 9 4,699 — — 4,708 (4,708 ) Lender Fee - November 2019 Senior Secured Convertible Note - Series B — — — — — (700 ) Fair Value at March 31, 2020 $ 63 $ 20,600 — $ — $ 20,663 Other Income (Expense) - Change in fair value - three months ended March 31, 2020 $ (8,008 ) Face value principal – issue date — — 4,111 — 4,111 Fair value adjustment – issue date — — (411 ) — (411 ) 411 Installment repayments – common stock (50 ) (5,695 ) — — (5,745 ) Non-installment payments – common stock (2 ) (242 ) — — (244 ) Non-installment payments – cash — — (54 ) — (54 ) Change in fair value (11 ) (2,363 ) 254 — (2,120 ) 2,120 Lender Fee - April 2020 Senior Convertible Note — — — — — (411 ) Fair Value at June 30, 2020 $ — $ 12,300 3,900 $ — $ 16,200 Other Income (Expense) - Change in fair value - three months ended June 30, 2020 $ 2,120 Face value principal – issue date — — — 7,750 7,750 Fair value adjustment – issue date — — — (750 ) (750 ) 750 Installment repayments – common stock — (2,298 ) — — (2,298 ) Non-installment payments – common stock — (141 ) — — (141 ) Non-installment payments – cash — — (81 ) (93 ) (174 ) Change in fair value — (2,961 ) 781 1,813 (367 ) 367 Lender Fee - August 2020 Senior Secured Convertible Note — — — — — (750 ) Fair Value at September 30, 2020 $ — $ 6,900 $ 4,600 $ 8,720 $ 20,220 Other Income (Expense) - Change in fair value - three months ended September 30, 2020 $ 367 Other Income (Expense) - Change in fair value - nine months ended September 30, 2020 $ (5,520 ) The changes in the fair value of debt during the three and nine months ended September 30, 2019 is as follows: December 2018 Senior Secured Convertible Note Other Income (Expense) Fair Value - December 31, 2018 $ 7,903 Installment repayments - common stock (52 ) Non-installment payments - common stock — Non-installment payments - cash (159 ) Change in fair value 559 $ (559 ) Fair Value - March 31, 2019 $ 8,251 Other Income (Expense) - Change in fair value $ (559 ) Installment repayments - common stock (1,480 ) Non-installment payments - common stock (22 ) Non-installment payments - cash (120 ) Change in fair value 161 $ (161 ) Fair Value - June 30, 2019 $ 6,790 Other Income (Expense) - Change in fair value $ (161 ) Installment repayments - common stock (1,850 ) Non-Installment repayments – common stock (90 ) Non-installment payments – cash — Change in fair value (379 ) $ 379 Fair Value - September 30, 2019 $ 4,472 Other Income (Expense) - Change in fair value – three months ended $ 379 Other Income (Expense) - Change in fair value - nine months ended September 30, 2019 $ (341 )

Stockholders' Equity, Common _2

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Schedule of Outstanding Warrants to Purchase Common Stock	The following table summarizes outstanding warrants to purchase common stock of the Company (classified in permanent equity) at the dates indicated: Common Stock Purchase Warrants Issued and Outstanding at Weighted Weighted Average Average September 30, Exercise December 31, Exercise Expiration 2020 Price /Share 2019 Price Date Series Z Warrants 16,814,939 $ 1.60 16,815,039 $ 1.60 April 2024 UPO - Series Z Warrants 53,000 $ 1.60 53,000 $ 1.60 January 2022 Series W Warrants 381,818 $ 5.00 381,818 $ 5.00 January 2022 Series S Warrants — $ — 1,199,383 $ 0.01 June 2032 Total 17,249,757 $ 1.68 18,449,240 $ 1.57
Schedule of Noncontrolling Interest	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is with respect to the Company’s majority-owned subsidiaries Lucid Diagnostics Inc. and Solys Diagnostics Inc., summarized for the periods indicated as follows: Nine Months Ended Year Ended NCI - equity (deficit) - beginning of period $ (814 ) $ (161 ) Minority Interest investment in Solys Diagnostics Inc. — 889 Minority Interest share subscription receivable - Solys Diagnostics Inc. — (889 ) Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise 5 — Net loss attributable to NCI - Lucid Diagnostics Inc. (1,007 ) (801 ) Net loss attributable to NCI - Solys Diagnostics Inc. (86 ) (10 ) Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 39 158 NCI - equity (deficit) - end of period $ (1,863 ) $ (814 )

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The following table sets forth the computation of earnings (loss) per share attributable to PAVmed Inc. and loss per share attributable to PAVmed Inc. common stockholders for the respective periods indicated: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Numerator Net loss - before noncontrolling interest $ (5,874 ) $ (3,271 ) $ (26,629 ) $ (10,714 ) Net loss attributable to noncontrolling interest 391 186 1,093 501 Net loss - as reported, attributable to PAVmed Inc. $ (5,483 ) $ (3,085 ) $ (25,536 ) $ (10,213 ) Series B Convertible Preferred Stock dividends: $ (74 ) $ (68 ) $ (215 ) $ (201 ) Net loss attributable to PAVmed Inc. common stockholders $ (5,557 ) $ (3,153 ) $ (25,751 ) $ (10,414 ) Denominator Weighted average common shares outstanding, basic and diluted 48,380,677 31,030,929 45,563,961 29,211,694 Loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.11 ) $ (0.10 ) $ (0.56 ) $ (0.35 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.11 ) $ (0.10 ) $ (0.57 ) $ (0.36 )
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The following common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive: September 30, 2020 2019 PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards 8,090,195 5,853,529 Unit purchase options - as to shares of common stock 53,000 53,000 Unit purchase options - as to shares underlying Series Z Warrants 53,000 53,000 Series Z Warrants 16,814,939 16,815,039 Series W Warrants 381,818 381,818 Series B Convertible Preferred Stock 1,203,488 1,135,482 Total 26,596,440 24,291,868

The Company and Description o_2

The Company and Description of the Business (Details Narrative)	9 Months Ended
	Sep. 30, 2020Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	1 Months Ended
	May 31, 2018$ / sharesshares
Case Western Reserve University [Member]
Number of common stock shares issued	943,464
Physician Inventors of the EsoGuard Technology [Member]
Number of common stock shares issued	289,679
Purchase price | $ / shares	$ 0.001

Related Party Transactions - Sc

Related Party Transactions - Schedule of Incurred Expenses of Minority Shareholders (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Related Party Transactions [Abstract]
Reimbursement - CWRU patent legal fees	$ 79	$ 20	$ 138	$ 98
EsoCheck devices provided to CWRU			15
EsoGuard Technology Physician Inventors' consulting agreements fees	20	24	74	98
EsoGuard Technology Physician Inventors' stock based compensation expense	6	3	17	51
Total	$ 105	$ 47	$ 244	$ 247

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Rent expense	$ 46	$ 34	$ 145	$ 98
October 1, 2020 to September 30, 2021 [Member]
Future minimum lease payments	$ 158		$ 158

Stock-Based Compensation - (Det

Stock-Based Compensation - (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	May 01, 2020	May 01, 2020	Mar. 15, 2019	Nov. 01, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jul. 24, 2020	Jul. 23, 2020
Proceeds from issuance of common stock									$ 5,480
Stock-based compensation expense						$ 586	$ 330	1,458	1,177
General and Administrative Expenses [Member]
Stock-based compensation expense						448	269	1,132	853
Research and Development Expenses [Member]
Stock-based compensation expense						$ 138	61	$ 326	$ 324
Employee Stock Purchase Plan [Member]
Vesting portion of stock								ESPP share purchase dates are March 31 and September 30. On the March 31, 2020 ESPP purchase date, 154,266 shares of PAVmed Inc. common stock were issued for proceeds of approximately $125; and on the September 30, 2020 ESPP purchase date, 152,289 shares of PAVmed Inc. common stock were issued for proceeds of approximately $231.
Number of common stock reserved						500,000		500,000
Number of stock purchase of common stock					154,266			152,289
Purchase price per share percentage on ESPP plan								85.00%
Proceeds from issuance of common stock					$ 125			$ 231
Common Stock [Member] | Employee Stock Purchase Plan [Member]
Number of common stock reserved										750,000	250,000
2014 Equity Plan [Member]
Aggregate intrinsic value						$ 1,598		1,598
Aggregate intrinsic value, vested and exercisable stock options						$ 922		$ 922
Stock options granted								1,470,000
Stock option granted, contractual term								10 years
Stock option granted, weighted average exercise price								$ 2.16
Vesting portion of stock								2014 Equity Plan, with each such stock option grant having a ten year contractual term from date-of-grant, vesting ratably over twelve quarters commencing with the grant date quarter, and a weighted average exercise price of $2.16 per share of common stock of PAVmed Inc.
Weighted average fair value of stock options								$ 1.28	$ 0.48
Expected dividend rate								0.00%
2014 Equity Plan [Member] | Non-employees [Member]
Weighted average fair value of stock options									$ 1.87
Contractual term									8 years 7 months 6 days
Expected stock price volatility									60.00%
Risk free interest rate									2.20%
Expected dividend rate									0.00%
2014 Equity Plan [Member] | Restricted Stock [Member]
Number of restricted stock award granted	950,000		700,000
Number of common stock reserved						2,000,000		2,000,000		9,951,081	7,951,081
Stock-based compensation expense	$ 1,938		$ 742
2014 Equity Plan [Member] | Restricted Stock [Member] | General and Administrative Expenses [Member]
Stock-based compensation expense						$ 185	$ 62	$ 391	$ 144
2014 Equity Plan [Member] | Restricted Stock [Member] | Research and Development Expenses [Member]
Stock-based compensation expense						$ 39		$ 64
2014 Equity Plan [Member] | Restricted Stock [Member] | Employees [Member]
Number of restricted stock award granted		950,000	700,000
Vesting portion of stock		2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of May 1, 2021.	2014 Equity Plan, with such restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of March 15, 2020.
Restricted stock awards vested			233,334
2014 Equity Plan [Member] | Subsequent Event [Member] | Common Stock [Member]
Stock options granted				200,000
Stock option granted, contractual term				10 years
Stock option granted, weighted average exercise price				$ 1.84
Vesting portion of stock				Vesting ratably over twelve quarters commencing with the grant date quarter, and a weighted average exercise price of $1.84 per share of common stock of PAVmed Inc.
2018 Long-Term Incentive Equity Plan [Member]
Contractual term of stock options								10 years
Weighted average fair value of stock options								$ 0.30	$ 0.36
2018 Long-Term Incentive Equity Plan [Member] | Non-employees [Member]
Weighted average fair value of stock options									$ 0.36
Contractual term									6 years
Expected stock price volatility									62.00%
Risk free interest rate									2.00%
Expected dividend rate									0.00%
2018 Stock Plan [Member]
Proceeds from issuance of common stock								$ 5
Number of common stock issued								3,333

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Summarizes Information About Stock Options (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	5,203,529
Number of Stock Options, Granted | shares	1,470,000
Number of Stock Option, Exercised | shares
Number of Stock Option, Forfeited | shares
Number of Stock Options Outstanding, Ending Balance | shares	6,673,529
Number of Stock Options Vested and exercisable stock options | shares	4,430,981
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.68
Weighted Average Exercise Price, Granted | $ / shares	2.16
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	2.58
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 3
Remaining Contractual Term (Years) stock options, Beginning	8 years 1 month 6 days
Remaining Contractual Term (Years) stock options, Ending Balance	7 years 6 months
Remaining Contractual Term (Years), Vested and exercisable stock options	6 years 8 months 12 days
2018 Stock Plan [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	995,000
Number of Stock Options, Granted | shares
Number of Stock Option, Exercised | shares	(3,333)
Number of Stock Option, Forfeited | shares
Number of Stock Options Outstanding, Ending Balance | shares	991,667
Number of Stock Options Vested and exercisable stock options | shares	706,242
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.86
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares	1.50
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	0.86
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 0.83
Remaining Contractual Term (Years) stock options, Beginning	9 years
Remaining Contractual Term (Years) stock options, Ending Balance	8 years 2 months 12 days
Remaining Contractual Term (Years), Vested and exercisable stock options	8 years 1 month 6 days

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock-Based Compensation Awards Granted (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 586	$ 330	$ 1,458	$ 1,177
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	448	269	1,132	853
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 138	$ 61	$ 326	$ 324

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Unrecognized Compensation Expense (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
2014 Long Term Incentive Equity Plan [Member] | Parent Company [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 2,075
Weighted Average Remaining Service Period	1 year
2014 Long Term Incentive Equity Plan [Member] | Parent Company [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 2,019
Weighted Average Remaining Service Period	2 years 4 months 24 days
2018 Long Term Incentive Equity Plan [Member] | Stock Options [Member] | Lucid Diagnostics Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 62
Weighted Average Remaining Service Period	1 year 1 month 6 days

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 9 months 18 days	5 years 8 months 12 days
Expected stock price volatility	73.00%	50.00%
Risk free interest rate	5.00%	2.40%
Expected dividend yield	0.00%	0.00%
2018 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 2 months 12 days	6 years
Expected stock price volatility	60.00%	62.00%
Risk free interest rate	1.90%	2.00%
Expected dividend yield	0.00%	0.00%

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands		Sep. 30, 2020	Dec. 31, 2019
Fair value of liability	[1]	$ 20,220	$ 8,139
November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	6,900	6,439
April 2020 Senior Convertible Notes [Member]
Fair value of liability	[1]	4,600
August 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	8,720
December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]		1,700
Fair Value, Inputs, Level 1 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | April 2020 Senior Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | August 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | April 2020 Senior Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | August 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 3 [Member]
Fair value of liability	[1]	20,220	8,139
Fair Value, Inputs, Level 3 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	6,900	6,439
Fair Value, Inputs, Level 3 [Member] | April 2020 Senior Convertible Notes [Member]
Fair value of liability	[1]	4,600
Fair Value, Inputs, Level 3 [Member] | August 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]	$ 8,720
Fair Value, Inputs, Level 3 [Member] | December 2018 Senior Convertible Note [Member]
Fair value of liability	[1]		$ 1,700
[1]	As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. There were no transfers between the respective Levels during the nine-month period ended September 30, 2020.

Financial Instruments Fair Va_4

Financial Instruments Fair Value Measurements - Schedule of Fair Value Assumption Used (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
November 2019 Senior Secured Convertible Note Series A & Series B [Member]
Required rate of return	0.12%
Conversion Price	$ 1.60
Expected term (years)	9 months 14 days
Volatility	70.00%
Risk free rate	0.12%
Dividend yield	0.00%
April 2020 Senior Convertible Notes [Member]
Required rate of return	65.00%
Conversion Price	$ 5
Expected term (years)	1 year 6 months 29 days
Volatility	65.00%
Risk free rate	0.13%
Dividend yield	0.00%
August 2020 Senior Secured Convertible Notes [Member]
Required rate of return	40.00%
Conversion Price	$ 5
Expected term (years)	1 year 10 months 6 days
Volatility	65.00%
Risk free rate	0.13%
Dividend yield	0.00%
December 2018 Senior Secured Convertible Note [Member]
Required rate of return		11.10%
Conversion Price		$ 1.60
Expected term (years)		1 year 6 months 3 days
Volatility		53.00%
Risk free rate		1.80%
Dividend yield		0.00%

Outstanding Debt - Summary of O

Outstanding Debt - Summary of Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended	12 Months Ended
		Sep. 30, 2020	Dec. 31, 2019
Face Value		$ 17,867	$ 8,692
Carrying Value		$ 20,220	$ 8,139
December 2018 Senior Secured Convertible Note [Member]
Maturity Date	[1]	Dec. 31, 2020	Dec. 31, 2020
Stated Interest Rate	[1]	7.875%	7.875%
Conversion Price	[1]	$ 1.60	$ 1.60
Face Value	[1]		$ 1,692
Carrying Value	[1]		$ 1,700
November 2019 Senior Secured Convertible Notes [Member]
Maturity Date	[2]	Sep. 30, 2021
Stated Interest Rate	[2]	7.875%
Conversion Price	[2]	$ 1.60
Face Value	[2]	$ 6,006
Carrying Value	[2]	$ 6,900
April 2020 Senior Convertible Notes [Member]
Maturity Date	[3]	Apr. 30, 2022
Stated Interest Rate	[3]	7.875%
Conversion Price	[3]	$ 5
Face Value	[3]	$ 4,111
Carrying Value	[3]	$ 4,600
August 2020 Senior Secured Convertible Notes [Member]
Maturity Date	[4]	Aug. 6, 2022
Stated Interest Rate	[4]	7.875%
Conversion Price	[4]	$ 5
Face Value	[4]	$ 7,750
Carrying Value	[4]	$ 8,720
November 2019 Senior Secured Convertible Note [Member]
Maturity Date	[2]		Sep. 30, 2021
Stated Interest Rate	[2]		7.875%
Conversion Price	[2]		$ 1.60
Face Value			$ 7,000
Carrying Value	[2]		$ 6,439
[1]	With respect to the December 2018 Senior Secured Convertible Note, in the nine months ended September 30, 2020, approximately $1,692 of principal repayments and approximately $6 of non-installment payments were settled through the issuance of 2,075,198 shares of the Company's common stock with a fair value of approximately $2,901 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). The December 2018 Senior Secured Convertible Debt was paid in full as of June 4, 2020.
[2]	With respect to the November 2019 Senior Secured Convertible Note - Series A and Series B - in the nine months ended September 30, 2020, approximately $7,993 of Accelerated and Bi-Monthly Installment principal repayments and approximately $383 of non-installment payments were settled through the issuance of 5,337,484 shares of the Company's common stock with a fair value of approximately $11,774 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Subsequent to September 30, 2020, through November 4, 2020, approximately $1,720 of Accelerated and Bi-Monthly Installment principal repayments along with approximately $28 of corresponding non-installment payments were settled through the issuance of 1,182,266 shares of the Company's common stock with a fair value of approximately $2,266 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company).
[3]	On April 30, 2020, the Company entered into a Security Purchase Agreement for the issue of a Senior Convertible Note with a face value principal of approximately $4,111 and lender fees of approximately $411 (recognized as a current period other expense), resulting in $3,700 cash proceeds received by the Company. - referred to as the April 2020 Senior Convertible Note. Additionally, under a separate agreement, the Company incurred a current period expense of approximately $120 with respect to the placement agent advisory fee. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon.
[4]	The Company entered into a Securities Purchase Agreement ("SPA") with an institutional investor (the "Investor"), and pursuant to the SPA, on August 6, 2020, the Company issued to the Investor a Senior Secured Convertible Note (the "August 2020 Senior Secured Convertible Note") with a face value principal amount of $7,750 and $750 lender fee (recognized as a current period other expense), resulting in $7,000 cash proceeds received by the Company. On the maturity date, the Company will pay the holder in cash all remaining outstanding principal and unpaid interest thereon The August 2020 Senior Secured Convertible Note investor and its affiliates also hold the Company's November 2019 Senior Secured Convertible Notes the April 2020 Senior Convertible Note. The August 2020 Senior Secured Convertible Note contains certain representations and warranties, covenants and indemnities for similar transactions as well as the past transactions entered into with the investor. The August 2020 Senior Secured Convertible Note contains certain redemption rights similar to the April 2020 Senior Convertible Note and security interest with a first priority line in all of our assets, including all of the Company' current and future significant subsidiaries, similar to the November 2019 Senior Secured Convertible Notes.

Outstanding Debt - Summary of_2

Outstanding Debt - Summary of Outstanding Debt (Details) (Parenthetical) $ in Thousands

Aug. 06, 2020USD ($)

Nov. 04, 2020USD ($)shares

Apr. 30, 2020USD ($)

Mar. 30, 2020USD ($)

Sep. 30, 2020USD ($)

Jun. 30, 2020USD ($)

Mar. 31, 2020USD ($)

Mar. 29, 2020

Sep. 30, 2020USD ($)

Sep. 30, 2019USD ($)

Dec. 31, 2019USD ($)

Principal amount

$ 17,867

$ 17,867

$ 8,692

Stock issued during the period conversion of senior secured convertible note

Lender fee

Proceeds - issue of senior secured convertible notes

13,300

Security Purchase Agreement [Member]

Advisory fee

$ 120

Series B [Member]

Debt instrument maturity description

The (cash) payment of such 3.0% interest on the $7.0 million face value principal resulted in the recognition of approximately $53 of interest expense during the period January 1, 2020 through March 29, 2020, with such interest expense included in other income (expense) in the accompanying (unaudited) condensed consolidated statement of operations for the nine months ended September 30, 2020.

Cash payment, interest rate percentage

0.030

December 2018 Senior Secured Convertible Note [Member]

Lender fee

November 2019 Senior Convertible Notes [Member] | Subsequent Event [Member] | Series A and Series B [Member]

Stock issued during the period conversion of senior secured convertible note, shares | shares

1,182,266

Accelerated installment amount principal repayments - common stock

$ 2,266

November 2019 Senior Convertible Notes [Member] | Series A and Series B [Member]

Non-installment payments

383

Accelerated installment amount principal repayments - common stock

7,993

November 2019 Senior Convertible Notes [Member] | Series A and Series B [Member] | Subsequent Event [Member]

Non-installment payments

1,720

Accelerated installment amount principal repayments - common stock

$ 28

November 2019 Senior Secured Convertible Notes [Member]

Principal amount

[1]

$ 6,006

$ 6,006

Interest rate

[1]

7.875%

7.875%

November 2019 Senior Secured Convertible Notes [Member] | Series B [Member]

Lender fee

$ 700

Proceeds - issue of senior secured convertible notes

$ 6,300

August 2020 Senior Secured Convertible Note [Member] | Security Purchase Agreement [Member] | Investor [Member]

Principal amount

$ 7,750

Lender fee

750

Proceeds - issue of senior secured convertible notes

$ 7,000

[1]

With respect to the November 2019 Senior Secured Convertible Note - Series A and Series B - in the nine months ended September 30, 2020, approximately $7,993 of Accelerated and Bi-Monthly Installment principal repayments and approximately $383 of non-installment payments were settled through the issuance of 5,337,484 shares of the Company's common stock with a fair value of approximately $11,774 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Subsequent to September 30, 2020, through November 4, 2020, approximately $1,720 of Accelerated and Bi-Monthly Installment principal repayments along with approximately $28 of corresponding non-installment payments were settled through the issuance of 1,182,266 shares of the Company's common stock with a fair value of approximately $2,266 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company).

Outstanding Debt - Schedule of

Outstanding Debt - Schedule of Senior Convertible Note Estimated Fair Value (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended						9 Months Ended
	Mar. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Fair Value - Beginning		$ 16,200	$ 20,663	$ 8,139				$ 8,139
Face value principal - issue date		7,750	4,111	7,000
Fair value adjustment at issue date		(750)	(411)	2,600
Installment repayments - common stock		(2,298)	(5,745)	(1,642)
Non-installment repayments - common stock		(141)	(244)	(4)
Non-installment repayments - cash		(174)	(54)	(138)
Change in fair value		(367)	(2,120)	4,708
Lender Fee
Fair Value - Ending		20,220	16,200	20,663				20,220
December 2018 Senior Secured Convertible Note [Member]
Fair Value - Beginning			63	1,700	$ 6,790	$ 8,251	$ 7,903	1,700	$ 7,903
Face value principal - issue date
Fair value adjustment at issue date
Installment repayments - common stock			(50)	(1,642)	(1,850)	(1,480)	(52)
Non-installment repayments - common stock			(2)	(4)	(90)	(22)
Non-installment repayments - cash						(120)	(159)
Change in fair value			(11)	9	(379)	161	559
Lender Fee
Fair Value - Ending	$ 8,251			63	4,472	6,790	$ 8,251		4,472
November 2019 Senior Secured Convertible Note Series A & Series B [Member] | Series A and Series B [Member]
Fair Value - Beginning		12,300	20,600	6,439				6,439
Face value principal - issue date				7,000
Fair value adjustment at issue date				2,600
Installment repayments - common stock		(2,298)	(5,695)
Non-installment repayments - common stock		(141)	(242)
Non-installment repayments - cash				(138)
Change in fair value		(2,961)	(2,363)	4,699
Lender Fee
Fair Value - Ending		6,900	12,300	20,600				6,900
April 2020 Senior Convertible Notes [Member]
Fair Value - Beginning		3,900
Face value principal - issue date			4,111
Fair value adjustment at issue date			(411)
Installment repayments - common stock
Non-installment repayments - common stock
Non-installment repayments - cash		(81)	(54)
Change in fair value		781	254
Lender Fee
Fair Value - Ending		4,600	3,900					4,600
August 2020 Senior Secured Convertible Notes [Member]
Fair Value - Beginning
Face value principal - issue date		7,750
Fair value adjustment at issue date		(750)
Installment repayments - common stock
Non-installment repayments - common stock
Non-installment repayments - cash		(93)
Change in fair value		1,813
Lender Fee
Fair Value - Ending		8,720						8,720
Other Expense [Member]
Fair value adjustment at issue date		750	411	(2,600)
Change in fair value	(559)	367	2,120	(4,708)	379	(161)
Lender Fee		(750)	(411)	(700)
Other Income (Expense) - Change in fair value - Senior Secured Convertible Notes and Senior Convertible Notes	$ (559)	$ 367	$ 2,120	$ (8,008)	$ 379	$ (161)		$ (5,520)	$ (341)

Cares Act Paycheck Protection_2

Cares Act Paycheck Protection Program Loan (Details Narrative) - USD ($) $ in Thousands	Apr. 08, 2020	Sep. 30, 2020	Dec. 31, 2019
Current portion - cares act paycheck protection program note payable		$ 200
Non-current portion - cares act paycheck protection program note payable		$ 100
Loan Agreement [Member] | JP Morgan Chase, N.A [Member] | PPP Loan [Member]
Proceeds from loan	$ 300
Debt instrument maturity date	Apr. 8, 2022
Interest rate	1.00%

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Oct. 31, 2020	Sep. 30, 2020	Oct. 01, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, shares authorized		20,000,000				20,000,000
Preferred stock, par value		$ 0.001				$ 0.001
Series B Convertible Preferred Stock [Member]
Dividend payable				$ 211
Series B Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.001				$ 0.001
Preferred stock, shares issued		1,203,488				1,158,209
Preferred stock, shares outstanding		1,203,488				1,158,209
Series B Convertible Preferred Stock [Member]
Dividends declared		$ 211
Dividend payable			$ 74		$ 211	$ 211
Additional shares of dividend	24,587	70,729

Stockholders' Equity, Common _3

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest (Details Narrative) - $ / shares	9 Months Ended
	Sep. 30, 2020	Jul. 24, 2020	Dec. 31, 2019
Common shares authorized	150,000,000		150,000,000
Common stock, par value per share	$ 0.001		$ 0.001
Common stock, shares issued	49,655,915		40,478,861
Common stock, shares outstanding	49,655,915		40,478,861
Series S Warrants [Member]
Warrants exercised	1,199,383
Series Z Warrants [Member]
Warrants exercised	100
Common Stock [Member]
Common shares authorized		50,000,000

Stockholders' Equity, Common _4

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Summarizes Outstanding Warrants to Purchase Common Stock (Details) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Common stock purchase warrants issued and outstanding	17,249,757	18,449,240
Weighted average exercise price per share	$ 1.68	$ 1.57
Series Z Warrants [Member]
Common stock purchase warrants issued and outstanding	16,814,939	16,815,039
Weighted average exercise price per share	$ 1.60	$ 1.60
Warrants expiration date	Apr. 30, 2024	Apr. 30, 2024
UPO - Series Z Warrants [Member]
Common stock purchase warrants issued and outstanding	53,000	53,000
Weighted average exercise price per share	$ 1.60	$ 1.60
Warrants expiration date	Jan. 31, 2022	Jan. 31, 2022
Series W Warrants [Member]
Common stock purchase warrants issued and outstanding	381,818	381,818
Weighted average exercise price per share	$ 5	$ 5
Warrants expiration date	Jan. 31, 2022	Jan. 31, 2022
Series S Warrants [Member]
Common stock purchase warrants issued and outstanding		1,199,383
Weighted average exercise price per share		$ 0.01
Warrants expiration date	Jun. 30, 2032	Jun. 30, 2032

Stockholders' Equity, Common _5

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
NCI - equity (deficit) - beginning of period			$ (814)
Net loss attributable to NCI	$ (391)	$ (186)	(1,093)	$ (501)
NCI - equity (deficit) - end of period	(1,863)		(1,863)		$ (814)
Non-controlling Interest [Member]
NCI - equity (deficit) - beginning of period			(814)	$ (161)	(161)
NCI - equity (deficit) - end of period	$ (1,863)		(1,863)		(814)
Non-controlling Interest [Member] | Solys Diagnostics Inc. [Member]
Minority Interest investment in Solys Diagnostics Inc					889
Minority Interest share subscription receivable - Solys Diagnostics Inc.					(889)
Net loss attributable to NCI			(86)		(10)
Non-controlling Interest [Member] | Lucid Diagnostics Inc [Member]
Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise			5
Net loss attributable to NCI			(1,007)		(801)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan			$ 39		$ 158

Loss Per Share - Schedule of Co

Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest	$ (5,874)	$ (3,271)	$ (26,629)	$ (10,714)
Net loss attributable to noncontrolling interest	391	186	1,093	501
Net loss - as reported, attributable to PAVmed Inc.	(5,483)	(3,085)	(25,536)	(10,213)
Series B Convertible Preferred Stock dividends:	(74)	(68)	(215)	(201)
Net loss attributable to PAVmed Inc. common stockholders	$ (5,557)	$ (3,153)	$ (25,751)	$ (10,414)
Weighted average common shares outstanding basic and diluted	48,380,677	31,030,929	45,563,961	29,211,694
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc.	$ (0.11)	$ (0.10)	$ (0.56)	$ (0.35)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders	$ (0.11)	$ (0.10)	$ (0.57)	$ (0.36)

Loss Per Share - Schedule of An

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive securities excluded from computation of diluted weighted shares outstanding	26,596,440	24,291,868
PAVmed Inc. 2014 Equity Plan Stock Options and Restricted Stock Awards [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	8,090,195	5,853,529
Unit Purchase Options as to Shares of common stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	53,000	53,000
Unit Purchase Options as to Shares Underlying Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	53,000	53,000
Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	16,814,939	16,815,039
Series W Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	381,818	381,818
Series B Convertible Preferred Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	1,203,488	1,135,482